Videos

Davies explains the future of at-home dialysis access, including policy changes and technological innovation.

Experts discuss interpreting genetic testing in liver disease, the role of biopsy, and how to integrate variants into clinical decision-making.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

Davies breaks down the gaps to at-home dialysis access and the future of global collaboration.

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Singh discusses his analysis of all 3 parts of the NODE-301 phase 3 trial, investigating the recently approved CBB’s potential risk of hypotension.

O’Donoghue addresses the inherent limitations in the ACS guidelines, from the constant influx of further research to the ambiguity of certain treatment recommendations.

Survey data show a nearly 40% drop in adolescent depressive episodes post-pandemic, though clinicians should remain vigilant for disparities and unmet care needs, Yockey says.

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.

Butt discusses his secondary analysis of the FINEARTS-HF trial, which demonstrated consistent treatment efficacy in patients with and without a history of IHD.

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

Catch up on the most impactful trial readouts to come out of ACC 2026.

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.

Song speaks about JAK inhibitors and their safety in dermatology care settings, contextualizing previous data on adverse events.